Management

This page includes content on healthcare management, including health system, hospital, department and clinic business management and administration. Areas of focus are on cardiology and radiology department business administration. Subcategories covered in this section include healthcare economics, reimbursement, leadership, mergers and acquisitions, policy and regulations, practice management, quality, staffing, and supply chain.

RSS icon
Thumbnail

Woman says hospital lost her missing daughter’s body for a year

Gina Congi was told her daughter was discharged from Mercy San Juan Medical Center. A year later, Jessie Peterson’s body was found in cold storage, a pending lawsuit claims.

cleveland clinic settles for failing to disclose research funding

Humana settles allegations of Medicare fraud for $90M

The lawsuit was brought by a whistleblower accusing the insurer of lying to earn Medicare Part D contracts from the Centers for Medicare & Medicaid Services.

AI cardiology heart artificial intelligence deep learning

FDA approves new AI-powered imaging software from Nanox subsidiary

According to Nanox.AI, previously known as Zebra Medical Vision, the updated software helps "bridge the divide between radiology and cardiology."

pharmaceutical drug approval process

Drugmaker to ‘challenge’ FDA after only receiving tentative approval for inhaled PAH treatment

An exclusivity agreement is stopping Liquidia Corporation from gaining full FDA approval of its new inhalation powder for pulmonary arterial hypertension. The company said it is disappointed with the agency's decision and plans to "take quick action."

V-Wave has gained considerable attention or its Ventura Interatrial Shunt System, a small implantable device designed to reduce pressure on the left atrium and the lungs in patients with heart failure with reduced ejection fraction (HFrEF). The Ventura device includes a nitinol hourglass-shaped frame that anchors to the patient’s fossa ovalis in a way that prevents migration or embolization. It is implanted via an interventional procedure with fluoroscopy and echocardiography guidance.

Johnson & Johnson to acquire heart failure specialists V-Wave for up to $1.7B

V-Wave has gained considerable attention for its Ventura Interatrial Shunt System, a small implantable device designed to reduce pressure on the left atrium and lungs of HFrEF patients.

artificial intelligence healthcare future

Welcome to your teched-out world, baby

Smart machines have watched over the little bundle of joy practically since conception—and will be an omnipresent part of his or her life for decades to come. What can we tell this individual their life will be like?

money cybersecurity ransomware health IT data breach hacker

McLaren confirms it was hit with ransomware; disruptions to last until September

The Michigan-based health system is not sure what data may have been taken during the breach. An investigation is ongoing.

Thumbnail

Atlanta hospital lost piece of patient’s skull, lawsuit claims

A lawsuit claims surgeons at Emory University Hospital were forced to make a synthetic bone flap for a replacement surgery when they were unable to locate Fernando Cluster's real one.

Displaying 257 - 264 of 8453

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.